New β-Lactam–β-Lactamase Inhibitor Combinations
Tel Aviv University · Rabin Medical Center · +5 more institutions
Abstract
The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa .
Citation impact
- FWCI
- 18.26
- Percentile
- 100%
- References
- 307
Authors
6- DYDafna YahavCorresponding
Tel Aviv University, Rabin Medical Center
- CGChristian G. Giske
Karolinska University Hospital, Karolinska Institutet
- AGAlise Grāmatniece
Karolinska University Hospital, Karolinska Institutet, Pauls Stradiņš Clinical University Hospital, University of Latvia
- HAHenrietta Abodakpi
University of Houston
- VHVincent H. Tam
University of Houston
Topics & keywords
- Meropenem
- Cefepime
- Ceftazidime/avibactam
- Acinetobacter baumannii
- Pseudomonas aeruginosa
- Klebsiella pneumoniae
- Microbiology
- Imipenem
- Good health and well-being